TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from SynAct Pharma AB ( (SE:SYNACT) ).
SynAct Pharma AB’s Board of Directors has proposed an authorization for the acquisition and transfer of the company’s own shares, subject to approval at an Extraordinary General Meeting. This move aims to enhance the company’s capital structure, potentially increasing shareholder value and providing flexibility for future business transactions. The proposal includes a buy-back program with a maximum purchase value of SEK 10 million, and the company is positioning itself for strategic opportunities ahead of its ADVANCE phase 2b-study results expected in early 2026.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm, specializing in the resolution of inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, aiding patients in achieving immune balance.
YTD Price Performance: 134.24%
Average Trading Volume: 170,633
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.12B
Find detailed analytics on SYNACT stock on TipRanks’ Stock Analysis page.